A review of the clinical efficacy and safety of 5α-reductase inhibitors for the enlarged prostate

Clinical Therapeutics

Volumn 29, Issue 1, 2007, Pages 17-25

  Naslund, Michael J ^a   Miner, Martin ^b  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^b BROWN UNIVERSITY   (United States)

Author keywords

5 reductase inhibitor; benign prostatic hyperplasia; dutasteride; efficacy; enlarged prostate; safety

Indexed keywords

ALFUZOSIN; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; DOXAZOSIN; DUTASTERIDE; FINASTERIDE; STEROID 5ALPHA REDUCTASE; STEROID 5ALPHA REDUCTASE INHIBITOR; TAMSULOSIN; TERAZOSIN;

AGE; AGING; ALGORITHM; ARTICLE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DISEASE COURSE; DISEASE SEVERITY; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; EJACULATION DISORDER; ENZYME INHIBITION; GYNECOMASTIA; HUMAN; IMPOTENCE; LANGUAGE; LIBIDO DISORDER; MALE; MEDLINE; MONOTHERAPY; OUTCOME ASSESSMENT; PROSTATE HYPERTROPHY; RISK REDUCTION; SCORING SYSTEM; SYMPTOM; SYSTEMATIC REVIEW; TREATMENT DURATION; URINE RETENTION;

ADRENERGIC ALPHA-ANTAGONISTS; AGED; AGED, 80 AND OVER; AZASTEROIDS; DRUG THERAPY, COMBINATION; ENZYME INHIBITORS; FINASTERIDE; HUMANS; MALE; MIDDLE AGED; PROSTATIC HYPERPLASIA; RANDOMIZED CONTROLLED TRIALS;

EID: 33947170033     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2007.01.018     Document Type: Article

References (38)

1. Roehrborn C.G., Marks L., and Harkaway R. Enlarged prostate: A landmark national survey of its prevalence and impact on US men and their partners. Prostate Cancer Prostatic Dis. 9 (2006) 30-34
2. AUA Practice Guidelines Committee. AUA guideline on management of benign prostatic hyperplasia (2003). Chapter 1: Diagnosis and treatment recommendations. J Urol. 170 (2003) 530-547
3. Available at:. Kaplan S.A., Naslund M.J., Fleming M.O., et al. Practical guidelines for the treatment of enlarged prostate in the primary care setting. Accessed (March 28, 2006). http://www.doctor.medscape.com/viewarticle/505863_1
4. O'Leary M.P., Roehrborn C., Andriole G., et al. Improvements in benign prostatic hyperplasia-specific quality of life with dutasteride, the novel dual 5alphareductase inhibitor. BJU Int. 92 (2003) 262-266
5. Kirby R.S., and McConnell J.D. Benign Prostatic Hyperplasia (1995), Health Press, Oxford, UK
6. Rhodes T., Girman C.J., Jacobsen S.J., et al. Longitudinal prostate growth rates during 5 years in randomly selected community men 40 to 79 years old. J Urol. 161 (1999) 1174-1179
7. Roberts R.O., Jacobsen S.J., Jacobson D.J., et al. Longitudinal changes in peak urinary flow rates in a community based cohort. J Urol. 163 (2000) 107-113
8. Jacobsen S.J., Jacobson D.J., Girman C.J., et al. Natural history of prostatism: Risk factors for acute urinary retention. J Urol. 158 (1997) 481-487
9. Arrighi H.M., Metter E.J., Guess H.A., and Fozzard J.L. Natural history of benign prostatic hyperplasia and risk of prostatectomy: The Baltimore Longitudinal Study of Aging. Urology 38 Suppl 1 (1991) 4-8
10. Dull P., Reagan Jr. R.W., and Bahnson R.R. Managing benign prostatic hyperplasia. Am Fam Physician 66 (2002) 87-88
11. Gjertson C.K., Walmsley K., and Kaplan S.A. Benign prostatic hyperplasia: Now we can begin to tailor treatment. Cleve Clin J Med. 71 (2004) 857
12. Gjertson C.K., Walmsley K., and Kaplan S.A. Benign prostatic hyperplasia: Now we can begin to tailor treatment. Cleve Clin J Med. 71 (2004) 860
13. Gjertson C.K., Walmsley K., and Kaplan S.A. Benign prostatic hyperplasia: Now we can begin to tailor treatment. Cleve Clin J Med. 71 (2004) 863-865
14. Roehrborn C.G., McConnell J.D., Lieber M., et al. Serum prostate-specific antigen concentration is a powerful predictor of acute urinary reten tion and need for surgery in men with clinical benign prostatic hyperplasia. Urology 53 (1999) 473-480
15. Barry M.J., Fowler Jr. F.J., O'Leary M.P., et al., Measurement Committee of the American Urological Association. The American Urological Association symp tom index for benign prostatic hyperplasia. J Urol. 148 (1992) 1549-1557
16. Barry M.J., Fowler Jr. F.J., O'Leary M.P., et al., Measurement Committee of the American Urological Association. Correlation of the American Urological Association symptom index with self-administered versions of the Madsen-Iversen, Boyarsky and Maine Medical Assessment Program symptom indexes. J Urol. 148 (1992) 1558-1563
17. Available at:. American Urological Association. Results of treatment outcomes analyses. Accessed. Guideline on the management of benign prostatic hyperplasia (BPH) (May 12, 2006). http://www.auanet.org/guidelines/mainreports/bph
18. Djavan B., Chapple C., Milani S., and Marberger M. State of the art on the efficacy and tolerability of alphal adrenoceptor antagonists in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia. Urology 64 (2004) 1081-1088
19. Boyle P., Roehrborn C., Harkaway R., et al. 5-Alpha reductase inhibition provides superior benefits to alpha blockade by preventing AUR and BPH-related surgery. Eur Urol. 45 (2004) 620-626
20. Souverein P.C., Erkens J.A., de la Rosette J.J., et al. Drug treatment of benign prostatic hyperplasia and hospital admission for BPH-related surgery. Eur Urol. 43 (2003) 528-534
21. Carson III C., and Rittmaster R. The role of dihydrotestosterone in benign prostatic hyperplasia. Urology 61 Suppl 1 (2003) 2-7
22. Russell D.W., and Wilson J.D. Steroid 5 alpha-reductase: Two genes/two enzymes. Annu Rev Biochem 63 (1994) 25-61
23. Sawaya M.E., and Price V.H. Different levels of Salpha-reductase type I and II, aromatase, and androgen receptor in hair follicles of women and men with androgenetic alopecia. J Invest Dermatol 109 (1997) 296-300
24. Thiboutot D., Harris G., Iles V., et al. Activity of the type 1 5 alphareductase exhibits regional differ ences in isolated sebaceous glands and whole skin. J Invest Dermatol 105 (1995) 209-214
25. Thigpen A.E., Cala K.M., and Russell D.W. Characterization of Chinese hamster ovary cell lines expressing human steroid 5 alpha-reductase isozymes. J Biol Chem 268 (1993) 17404-17412
26. Clark R.V., Hermann D.J., Cunningham G.R., et al. Marked suppression of dihydrotestosterone in men with benign prostatic hyperplasia by dutasteride, a dual 5alphareductase inhibitor. J Clin Endocrinol Metab 89 (2004) 2179-2184
27. Roehrborn C.G., Boyle P., Nickel J.C., et al., ARIA3001, ARIA3002, and ARIA3003 Study Investigators. Efficacy and safety of a dual inhibitor of 5-alpha-reductase types 1 and 2 (dutasteride) in men with benign prostatic hyperplasia. Urology 60 (2002) 434-441
28. Nickel J.C., Fradet Y., Boake R.C., et al. Efficacy and safety of finasteride therapy for benign prostatic hyperplasia: Results of a 2-year randomized controlled trial (the PROSPECT study). PROscar Safety Plus Efficacy Canadian Two year Study. CMAJ 155 (1996) 1251-1259
29. McConnell J.D., Bruskewitz R., Walsh P., et al., Finasteride LongTerm Efficacy and Safety Study Group. The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. N Engl J Med 338 (1998) 557-563
30. Roehrborn C.G., Bruskewitz R., Nickel J.C., et al., Proscar Long-Term Efficacy and Safety Study Group. Sustained decrease in incidence of acute urinary retention and surgery with finasteride for 6 years in men with benign prostatic hyperplasia. J Urol 171 (2004) 1194-1198
31. Gormley G.J., Stoner E., Bruskewitz R.C., et al., Finasteride Study Group. The effect of finasteride in men with benign prostatic hyperplasia. N Engl J Med 327 (1992) 1185-1191
32. Stoner E., and Finasteride Study Group. Maintenance of clinical efficacy with finasteride therapy for 24 months in patients with benign prostatic hyperplasia. Arch Intern Med 154 (1994) 83-88
33. Debruyne F., Barkin J., van Erps P., et al., ARIA3001, ARIA3002, and ARIB3003 Study Investigators. Efficacy and safety of long-term treatment with the dual 5alpha-reductase inhibitor dutasteride in men with symptomatic benign prostatic hyperplasia. Eur Urol 46 (2004) 488-494
34. McConnell J.D., Roehrborn C.G., Bautista O.M., et al., Medical Therapy of Prostatic Symptoms (MTOPS) Research Group. The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med 349 (2003) 2387-2398
35. Barkin J., Guimaraes M., Jacobi G., et al. Alpha-blocker therapy can be withdrawn in the majority of men following initial combination therapy with the dual 5alpha-reductase inhibitor dutasteride. Eur Urol 44 (2003) 461-466
36. Baldwin K.C., Ginsberg P.C., and Harkaway R.C. Discontinuation of alphablockade after initial treatment with finasteride and doxazosin for bladder outlet obstruction. Urol Int 66 (2001) 84-88
37. Paris, France. Roehrborn C., Schulman C., Arrosagarai P., et al. Baseline data from the Combination of Avodart and Tamsu losin (COMBAT) trial: Relationships between body mass index (BMI) and LUTS/BPH measures. Presented at: European Association of Urology Annual Congress (April 5-8, 2006)
38. Andriole G.L., and Kirby R. Safety and tolerability of the dual 5alpha-reductase inhibitor dutasteride in the treatment of benign prostatic hyperplasia. Eur Urol 44 (2003) 82-88